Skip Navigation

Cardiovascular Research 2002 55(3):690-700; doi:10.1016/S0008-6363(02)00319-X
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schulz, R.
Right arrow Articles by Heusch, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schulz, R.
Right arrow Articles by Heusch, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2002, European Society of Cardiology

p38 MAP kinase is a mediator of ischemic preconditioning in pigs

Rainer Schulza, Sergej Belosjorowa, Petra Gresa, Johanna Jansena, Martin C Michelb and Gerd Heuscha,*

aAbteilungen für Pathophysiologie, Zentrum für Innere Medizin, Universitätsklinikum Essen, Hufelandstrasse 55, 45122 Essen, Germany
bNieren- und Hochdruckkrankheiten, Zentrum für Innere Medizin Universitätsklinikum Essen, 45122 Essen, Germany

gerd.heusch{at}uni-essen.de

* Corresponding author. Tel.: +49-201-723-4480; fax: +49-201-723-4481

Objective: The role of p38MAPK in ischemic preconditioning (IP) is still equivocal, insofar as the p38MAPK-inhibitor SB203580 abolished IP in rats, rabbits and dogs, but not in pigs. Blockade of p38MAPK prior to the sustained ischemia also generated contradictory findings, insofar as p38MAPK acted as trigger in dogs but as mediator in rats. We have now tested whether the two structurally unrelated p38MAPK-inhibitors, BIX-645 and SB203580, abolished infarct size (IS) reduction by IP in pigs and whether their effects depended on the time of administration. Methods: Sixty-five enflurane-anesthetized pigs underwent 90 min low-flow ischemia and 120 min reperfusion without or with one preceding cycle of 10 min preconditioning ischemia and 15 min reperfusion. Pigs received BIX-645 (1 mg/kg, i.v.) or SB203580 (10 µM, i.c.) prior to either IP or the sustained ischemia. Results: IS (% TTC-staining) was reduced by IP [4.8±3.1(S.E.M.), P<0.05] compared to placebo (25.8±5.5). BIX-645 or SB203580 per se had no effect on IS (23.5±5.2 and 21.8±4.4, respectively). IS reduction by IP was abolished by BIX-645 (26.2±6.4 or 25.5±4.7) and SB203580 (19.9±4.3 or 16.7±4.7), given either prior to IP or the sustained ischemia, respectively. The supernatant of homogenized myocardial biopsies taken during the sustained ischemia from preconditioned pigs receiving either BIX-645 or SB203580 inhibited the anisomycin-stimulated ATF-2 phosphorylation in cultured Rat1 fibroblasts. This in vitro inhibition of ATF-2 phosphorylation correlated to the actual IS. Conclusion: The attenuation of the IS-reducing effect of IP depends on the effectiveness of blockade of p38MAPK activity. p38MAPK is a mediator of IP in pigs.

KEYWORDS Ischemia; Preconditioning; Reperfusion; Signal transduction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
N. Suleman, S. Somers, R. Smith, L. H. Opie, and S. C. Lecour
Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning
Cardiovasc Res, July 1, 2008; 79(1): 127 - 133.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
M. Roesslein, M. Frick, V. Auwaerter, M. Humar, U. Goebel, C. Schwer, K. K. Geiger, H. L. Pahl, B. H. J. Pannen, and T. Loop
Sevoflurane-Mediated Activation of p38-Mitogen-Activated Stresskinase is Independent of Apoptosis in Jurkat T-Cells
Anesth. Analg., April 1, 2008; 106(4): 1150 - 1160.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Heidbreder, A. Naumann, K. Tempel, P. Dominiak, and A. Dendorfer
Remote vs. ischaemic preconditioning: the differential role of mitogen-activated protein kinase pathways
Cardiovasc Res, April 1, 2008; 78(1): 108 - 115.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. C. Zhao, G. Cheng, L. X. Zhang, Y. T. Tseng, and J. F. Padbury
Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury
Cardiovasc Res, December 1, 2007; 76(3): 473 - 481.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y.-J. Xu, H. K. Saini, M. Zhang, V. Elimban, and N. S. Dhalla
MAPK activation and apoptotic alterations in hearts subjected to calcium paradox are attenuated by taurine
Cardiovasc Res, October 1, 2006; 72(1): 163 - 174.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. A. Kaiser, J. M. Lyons, J. Y. Duffy, C. J. Wagner, K. M. McLean, T. P. O'Neill, J. M. Pearl, and J. D. Molkentin
Inhibition of p38 reduces myocardial infarction injury in the mouse but not pig after ischemia-reperfusion
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2747 - H2751.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Ballard-Croft, G. Kristo, Y. Yoshimura, E. Reid, B. J. Keith, R. M. Mentzer Jr., and R. D. Lasley
Acute adenosine preconditioning is mediated by p38 MAPK activation in discrete subcellular compartments
Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1359 - H1366.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Nakamura, T. Miura, A. Nakano, Y. Ichikawa, T. Yano, H. Kobayashi, Y. Ikeda, T. Miki, and K. Shimamoto
Role of microtubules in ischemic preconditioning against myocardial infarction
Cardiovasc Res, November 1, 2004; 64(2): 322 - 330.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Inserte, D. Garcia-Dorado, M. Ruiz-Meana, L. Agullo, P. Pina, and J. Soler-Soler
Ischemic preconditioning attenuates calpain-mediated degradation of structural proteins through a protein kinase A-dependent mechanism
Cardiovasc Res, October 1, 2004; 64(1): 105 - 114.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. O. McFalls, M. Hou, R. J. Bache, A. Best, D. Marx, J. Sikora, and H. B. Ward
Activation of p38 MAPK and increased glucose transport in chronic hibernating swine myocardium
Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1328 - H1334.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Guo, A. B. Stein, W.-J. Wu, W. Tan, X. Zhu, Q.-H. Li, B. Dawn, R. Motterlini, and R. Bolli
Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo
Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1649 - H1653.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. A Gorog, M. Tanno, X. Cao, M. Bellahcene, R. Bassi, A. M.N Kabir, K. Dighe, R. A Quinlan, and M. S Marber
Inhibition of p38 MAPK activity fails to attenuate contractile dysfunction in a mouse model of low-flow ischemia
Cardiovasc Res, January 1, 2004; 61(1): 123 - 131.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Skyschally, R. Schulz, P. Gres, H.-G. Korth, and G. Heusch
Attenuation of ischemic preconditioning in pigs by scavenging of free oxyradicals with ascorbic acid
Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H698 - H703.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. M Yellon and J. M Downey
Spotlight on preconditioning
Cardiovasc Res, August 15, 2002; 55(3): 425 - 428.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.